Kinase Chemistry – Just a year and a half behind the times.

I don’t know’s on third

Posted by kinasepro on June 19, 2007

Because? oh he’s centerfield…

So TM asked for it, and while most of these are scatterred about the site… It’s not such a bad idea to have all the not-yet-approved kinase inhibitors currently active in US phase three clinical trials here in one place:

In a maybe-not-so-chronoligical order: Arxxant, Enzastaurin, Recentin, Zactima, Axitinib, Motesanib, CP-690,550, Pazopanib, and Tasigna.

Missing any?

7 Responses to “I don’t know’s on third”

  1. Nice job!

  2. chalker said

    Yeah, nice one!
    Didn’t Novartis want their AMN-107 to be a ‘nib’? ie nilotinib to tasigna

  3. kinasepro said

    Erhm, not sure I catch your meaning…

    I don’t know who came up with it, but ‘nib’ is just sort of short for ‘inhibtor’ and has become a clinical name for kinase inihbitors. It differentiates them from the first gen *ostaurine’s and the *mab’s: monoclonal antibodies.

    Personally I prefer the #. Heck if it were up to me we’d all be using the original notebook numbers until something hits the market, but I’ve named the entries with the furthest advanced name available “drug” > “nib” > “#”

    So anyways, nilotinib is just the clinical name, and Tasigna will be the drug’s name.

  4. chalker said

    Cheers, now I get it.

  5. What about vatalanib and lestaurtinib (more info here although its a little unclear as to whether vatalanib is still in development It doesnt appear on the April 11 version of Novartis’s pipeline

  6. kinasepro said

    Vatalanib has something in common with a hot rock… On lestaurtinib / CEP-701, hmm… .gov shows just 1s and 2s, but I’m guessing its a 3 in the EU? as from the website:

    “Our Phase 3 study in acute myelogenous leukemia is slated for completion in late 2007”

  7. I found a reference to another one – Alvocidib – more commonly know as Flavopiridol. It is listed on the IDDB as being in Phase 3 for CLL in France (NCI and sanofi aventis), and it also appears on the S-A website pipeline.

    Oh, and vatalanib doesnt appear in the Novartis’ ASCO pipeline update presentation at all either. Draw from that what you will

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: